Glenmark Pharmaceuticals Limited (Glenmark), has launched a fixed dose combination (FDC) of its novel, patent protected, globally researched Sodium Glucose Co-Transporter Inhibitor(SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor)– Vildagliptin, with Metformin(first-line medication for the treatment of type 2diabetes).
This fixed drug combination is indicated for the management of Type 2 diabetes. The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo MV and Remozen MV. Mr. Alok Malik, Group Vice President & Business Head, India Formulations said, “We are proud to introduce this innovative fixed dose combination, which is cutting-edge, extensivelyresearched,at an affordable costand will significantly improve patient compliance and provide glycemic &extra glycemic benefits to patients with uncontrolled Type 2 diabetes, in India”.
Glenmark launch Remogliflozin + Vildagliptin + Metforminfixed dose combination
